Catalog No.
Product Name
Application
Product Information
Citations
-
Syk Inhibitor
R406 is an orally available spleen tyrosine kinase inhibitor with an IC50 of 41 nM.- Sina Ghasempour, .et al. , J Immunol, 2024, Oct 1;213(7):988-997 PMID: 39140892
- Gabriella Leung, .et al. , JCI insight, 2021, Dec 8;6(23):e149376 PMID: 34673575
-
Syk Inhibitor
R406 is an orally available spleen tyrosine kinase inhibitor with an IC50 of 41 nM. -
Syk Inhibitor
R935788 (Fostamatinib disodium) is a potent orally available inhibitor of Syk that inhibits tumor growth in the Eμ- TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling. -
Syk Inhibitor
BAY 61-3606 is a cell-permeable imidazopyrimidine compound that acts as a potent, ATP-competitive, reversible, and highly selective inhibitor of Syk tyrosine kinase activity with no inhibitory effect against Btk, Fyn, Itk, Lyn, and Src.- So-Jeong Park, .et al. , Ecotoxicol Environ Saf, 2023, Jul 15;260:115061 PMID: 37257343
- Ami Kobayashi, .et al. , Nat Commun, 2023, Jan 25;14(1):312 PMID: 36697396
- Ju-Won Jang, .et al. , Int Immunopharmacol, 2021, Mar 21;95:107509 PMID: 33761438
- Sojin Park, .et al. , Sci Rep, 2020, 10: 11784 PMID: 32678160
- Park S, .et al. , Free Radic Res, 2018, Sep 11:1-11 PMID: 30203714
-
Syk inhibitor
R788 (Fostamatinib) is an important spleen tyrosine kinase (Syk) inhibitor, showing efficacy against kinase-mediated IgG Fc gamma receptor signaling.- Shamima Azma Ansari, .et al. , Br J Cancer, 2025, Sep 9 PMID: 40926063
- Liyanage Manosika Buddhini Perera, .et al. , Biol Pharm Bull, 2024, 47(4):750-757 PMID: 38556260
- Mahon OR, .et al. , Acta Biomater, 2018, Jan;65:426-435 PMID: 29104084
- Emma M. Corr, .et al. , Arthritis Res Ther, 2017, 19: 23 PMID: 28173838
- Cunningham CC, .et al. , Osteoarthritis Cartilage, 2016, Dec;24(12):2141-2152 PMID: 27426968
- Corr EM, .et al. , Atherosclerosis, 2016, Aug;251:197-205 PMID: 27356299
-
Syk inhibitor
P505-15 (also known as PRT062607) is a novel, highly selective, and orally bioavailable small molecule SYK inhibitor (SYK IC(50) = 1 nM) with anti-SYK activity that is at least 80-fold greater than its affinity for other kinases.- Li T, .et al. , Oncogene, 2018, Nov;37(47):6180-6194 PMID: 30013190
-
Syk Inhibitor
Piceatannol is an anti-inflammatory, immunomodulatory and antiproliferative agent. Inhibits p56lck and syk protein tyrosine kinases and inhibits TNF-induced NF-??B activation and gene expression. -
Syk Inhibitor
PRT2607, also known as PRT062607, P505-15, and BIIB057, is a novel, highly selective, and orally bioavailable small molecule SYK inhibitor (SYK IC(50) = 1 nM) with anti-SYK activity that is at least 80-fold greater than its affinity for other kinases. -
SYK inhibitor
Lanraplenib (GS-9876) is a highly selective and orally active SYK inhibitor (IC50=9.5 nM) in development for the treatment of inflammatory diseases. -
Syk inhibitor
GS-9973 is an oral inhibitor of spleen tyrosine kinase (Syk), with potential antineoplastic activity. -
Dual Syk and JAK inhibitor
PRT062070 is a novel, oral, dual spleen tyrosine kinase (Syk) and janus kinase (JAK) inhibitor. Cerdulatinib preferentially inhibited JAK1 and JAK3 dependent cytokine mediated signaling and functional responses in various cell types. -
Syk Inhibitor
BAY 61-3606 is a potent (Ki = 7.5 nM) and selective inhibitor of Syk kinase. -
Syk inhibitor
PRT-060318 is a novel selective inhibitor of the tyrosine kinase Syk, as an approach to HIT treatment. -
SYK/JAK inhibitor
Gusacitinib (ASN-002) is a potent dual inhibitor of spleen tyrosine kinase (SYK) and janus kinase (JAK) with IC50 values of 5-46 nM. -
Syk inhibitor
Fostamatinib disodium hexahydrate (R788 disodium hexahydrate), a prodrug of the active metabolite R406, is a potent Syk inhibitor with IC50 of 41 nM. -
Syk inhibitor
TAK-659 hydrochloride is a potent, selective and orally available spleen tyrosine kinase (Syk) inhibitor with an IC50 of 3.2 nM. -
SYK inhibitor
GSK143 dihydrochloride is an orally active and highly selective inhibitor of spleen tyrosine kinase (SYK), exhibiting a pIC₅₀ of 7.5. It also inhibits phosphorylated ERK (pErk) with a pIC₅₀ of 7.1, indicating its ability to modulate downstream signaling pathways involved in immune responses. In preclinical models, GSK143 dihydrochloride effectively reduces inflammation and prevents the recruitment of immune cells to the intestinal muscularis, highlighting its potential as a therapeutic agent for inflammatory diseases, particularly those involving the gastrointestinal tract. -
Syk Inhibitor
Syk Inhibitor II dihydrochloride dihydrate is a selective and ATP-competitive inhibitor of Syk with an IC50 of 41 nM. This compound effectively inhibits 5-HT release from RBL cells, demonstrating an IC50 of 460 nM. With reduced potency against other kinases, it holds potential for applications in treating allergic responses and exploring the role of Syk in various immunological processes. -
Syk Inhibitor
Syk Inhibitor II hydrochloride is a highly selective ATP-competitive inhibitor of Syk kinase, exhibiting an IC50 of 41 nM. This compound effectively inhibits serotonin release from RBL cells, with an IC50 of 460 nM. Syk Inhibitor II hydrochloride demonstrates reduced potency against other kinases, making it a valuable tool for investigating Syk-mediated signaling pathways and exploring its anti-allergic properties in research applications. -
Syk Inhibitor
PRT-060318 dihydrochloride is a selective and potent inhibitor of the tyrosine kinase Syk, exhibiting an IC50 of 3 nM. This compound effectively suppresses B cell activation and migration in chronic lymphocytic leukemia (CLL) and induces apoptosis in these cells. Additionally, PRT-060318 dihydrochloride has demonstrated the ability to prevent Heparin-induced thrombocytopenia and thrombosis in transgenic mouse models, making it a valuable tool for research in CLL and thrombus formation. -
Syk Inhibitor
BAY 61-3606 hydrochloride is a highly selective Syk inhibitor that acts in an ATP-competitive manner with a Ki of 7.5 nM and an IC50 of 10 nM. It effectively reduces ERK1/2 and Akt phosphorylation in neuroblastoma cells and significantly decreases Syk phosphorylation in K-rn cell lysates. Additionally, BAY 61-3606 hydrochloride enhances TRAIL-induced apoptosis in breast cancer cells by downregulating Mcl-1, making it a valuable tool for investigating Syk-related pathways in cancer research. -
Syk Inhibitor
PRT062607 acetate is a potent Syk inhibitor with an IC50 of 1 nM, designed for oral administration. This compound effectively inhibits inflammatory pathways and induces apoptosis, demonstrating significant antitumor activity in tumor xenograft mouse models. It serves as a valuable tool in cancer research and the study of Syk-mediated signaling. -
SYK Inhibitor
GSK2646264 is a potent and selective inhibitor of spleen tyrosine kinase (SYK), exhibiting a pIC50 value of 7.1. This compound also shows inhibitory activity against several other kinases, including LCK, LRRK2, GSK3β, JAK2, VEGFR2, and Aurora kinases, with varying pIC50 values. Due to its ability to penetrate the epidermis and dermis, GSK2646264 is potentially valuable for research applications in dermatological conditions and immune responses. -
SYK/JAK Inhibitor
Gusacitinib hydrochloride is a potent dual inhibitor of SYK and JAK kinases, demonstrating IC50 values of 5 nM, 46 nM, 4 nM, 11 nM, and 8 nM for SYK, JAK1, JAK2, JAK3, and TYK2, respectively. This compound effectively suppresses critical inflammatory pathways linked to the pathogenesis of atopic dermatitis. Gusacitinib hydrochloride is suitable for research applications involving chronic hand eczema and various cancers, including basal cell carcinoma. -
SYK/JAK Inhibitor
SYK/JAK-IN-1 is a dual inhibitor targeting SYK and JAK2, exhibiting IC50 values of less than 5 nM for both kinases. This compound demonstrates significant anti-inflammatory and anti-proliferative activities, making it a valuable tool for research involving hematological malignancies and autoimmune disorders. Its potent inhibition profile allows for the exploration of signaling pathways associated with SYK and JAK2, facilitating studies in cancer biology and immunology. -
JAK3/Syk Inhibitor
R-348 choline is a potent, orally active inhibitor of Janus kinase 3 (JAK3) and spleen tyrosine kinase (Syk). This compound effectively reduces the expression levels of pro-inflammatory cytokines, including interferon-gamma (IFN-γ), interleukin-6 (IL-6), and interleukin-10 (IL-10). R-348 choline is primarily utilized in research related to acute cardiac allograft rejection and other autoimmune conditions where JAK3 and Syk signaling play critical roles. -
P38-α/Syk Inhibitor
TOP1362 is a potent inhibitor targeting P38-α and Syk kinases, with Kd values of 26 nM and 18 nM, respectively. The compound demonstrates an IC50 of 14 nM in Src kinase activity assays, showcasing its efficacy in inhibiting P38-α, Src, and Syk. TOP1362 is applicable in research focused on dry eye syndrome and related pathways. -
Syk Inhibitor
TAS05567 is a highly selective, ATP-competitive inhibitor of Syk, exhibiting an IC50 of 0.37 nM. This compound demonstrates potent inhibition of Syk alongside four other kinases (FLT3, JAK2, KDR, and RET) at IC50 values of 10 nM, 4.8 nM, 600 nM, and 29 nM, respectively. TAS05567 is suitable for research applications related to humoral immune-mediated inflammatory conditions, including various autoimmune and allergic diseases. -
SYK Inhibitor
GSK143 is a highly selective inhibitor of spleen tyrosine kinase (SYK) with an oral bioavailability and a pIC50 of 7.5. It effectively inhibits phosphorylated Erk (pErk) with a pIC50 of 7.1. GSK143 demonstrates significant anti-inflammatory properties and has been shown to reduce immune cell recruitment in the intestinal muscularis in murine models, making it a valuable tool for research in inflammatory diseases and immune response modulation. -
Syk Inhibitor, NF-κB p65 Inhibitor, TGF-β1/Smad Signaling Inhibitor
Flavanomarein is a potent inhibitor of Syk and NF-κB p65, as well as a modulator of TGF-β1/Smad signaling pathways. This compound exhibits cytoprotective, anti-inflammatory, and antioxidant activities, enhancing AKT phosphorylation while regulating key proteins such as PKC-δ, P85α, PKC-β1, Sirt1, Bcl-2, and ICAD. Flavanomarein also inhibits the nuclear translocation of NF-κB p65 and modulates epithelial-mesenchymal transition (EMT) markers, promoting proliferation in HK-2 cells and protecting neuronal cells from 6-OHDA-induced neurotoxicity. This compound is valuable for research on Parkinson's disease and diabetic nephropathy. -
Syk Inhibitor
Syk Inhibitor II is a highly selective, ATP-competitive inhibitor of spleen tyrosine kinase (Syk) with an IC50 of 41 nM. It effectively inhibits 5-hydroxytryptamine (5-HT) release from rat basophilic leukemia (RBL) cells, demonstrating an IC50 of 460 nM. This compound exhibits a lower potency against other kinases, making it a valuable tool for studying Syk-mediated signaling pathways and exploring its potential in anti-allergic research applications. -
Syk Inhibitor
Syk Inhibitor II dihydrochloride is a highly selective, ATP-competitive inhibitor of Spleen Tyrosine Kinase (Syk) with an IC50 of 41 nM. It effectively inhibits 5-HT release from rat basophilic leukemia (RBL) cells, demonstrating an IC50 of 460 nM. This compound exhibits reduced potency against other kinases, making it a valuable tool for research applications in immunology and allergy research, particularly in studies investigating Syk's role in signaling pathways associated with allergic responses. -
Chemical Probe
MRL-SYKi is a selective chemical probe targeting spleen tyrosine kinase (SYK). It demonstrates potent binding to gain-of-function variants of SYK, with IC50 values of 2.1 nM for SYK(S550Y), 14 nM for SYK(S550F), and 4.6 nM for SYK(P342T) in digitonin-permeabilized cell assays. MRL-SYKi effectively inhibits catalytic activity, achieving IC50 values of 63 nM and 95 nM for SYK(S550F) and SYK(P342T) respectively in phospho-specific assays. This compound is valuable for advancing research on inflammation and related signaling pathways. -
Syk Inhibitor
Sovleplenib is a selective Spleen Tyrosine Kinase (SYK) inhibitor with an IC50 of 25 nM, demonstrating high potency and oral bioavailability. This compound exhibits significant anti-tumor activity and is useful in the research of immune thrombocytopenia (ITP). Its targeted mechanism makes it a valuable tool for studying the roles of SYK in various immune-mediated conditions. -
Syk Inhibitor
Syk-IN-4 is a selective, orally bioavailable inhibitor of SYK, exhibiting an IC50 of 0.31 nM. This compound demonstrates significant potential in modulating immune responses and is being investigated for its therapeutic applications in autoimmunity and hematological malignancies. Syk-IN-4 serves as a valuable tool for researchers exploring the role of SYK in disease progression and treatment strategies. -
Syk Inhibitor
Cevidoplenib is a selective spleen tyrosine kinase (Syk) inhibitor, offering potential anti-inflammatory and immunomodulatory effects. This compound impedes B cell receptor (BCR)-mediated survival, proliferation, and differentiation of B cells, making it useful in research focused on immune responses and related disorders. Additionally, Cevidoplenib demonstrates inhibitory activity on multiple kinases, including Jak2, Jak3, and RET, with varying degrees of potency, providing a versatile tool for investigating kinase signaling pathways in cellular biology. -
Syk Inhibitor
OXSI-2 is a potent Syk inhibitor that exhibits a bioavailable and cell-permeable profile, with an EC50 value of 313 nM and an IC50 of 14 nM. This compound effectively modulates Syk activity, making it a valuable tool for studying signaling pathways in immune responses and cancer. OXSI-2 is suitable for research applications focused on elucidating the role of Syk in disease processes and therapeutic interventions. -
SYK Inhibitor
Lanraplenib succinate is a highly selective, orally active SYK inhibitor with an IC50 of 9.5 nM. It targets SYK activity in platelets through the glycoprotein VI (GPVI) receptor, demonstrating potential therapeutic effects in inflammatory diseases. Notably, Lanraplenib succinate does not prolong bleeding time in preclinical models, indicating a favorable safety profile for clinical applications. -
Syk Inhibitor
Cevidoplenib dimesylate is a selective inhibitor of spleen tyrosine kinase (Syk), demonstrating potential in modulating inflammatory and immune responses. This compound is primarily utilized in research focused on autoimmune diseases and allergic disorders, offering insights into the therapeutic mechanisms of Syk inhibition. Additionally, cevidoplenib may facilitate investigations into the role of Syk in various signaling pathways within the immune system. -
SYK Iinhibitor
ER-27319 maleate is a selective inhibitor of spleen tyrosine kinase (SYK), effectively blocking its tyrosine phosphorylation and subsequent activity. This compound demonstrates significant biological activity by inhibiting the release of antigen-induced allergic mediators from both human and rat mast cells, with an IC50 value of 10 μM. ER-27319 maleate is valuable for research in allergic diseases and inflammation pathways. -
SYK Iinhibitor
ER-27319 is a potent and selective Spleen Tyrosine Kinase (SYK) inhibitor, known for its ability to suppress the tyrosine phosphorylation of SYK and thereby inhibit its enzymatic activity. This compound effectively blocks the release of antigen-induced allergic mediators from human and rat mast cells, exhibiting an IC50 of 10 μM. ER-27319 is a valuable tool for research in the field of allergic diseases, particularly in studies focused on mast cell activation and modulation. -
Syk Inhibitor
Syk-IN-1 is a highly potent inhibitor of Syk (spleen tyrosine kinase), demonstrating an IC50 value of 35 nM. This compound effectively disrupts Syk-mediated signaling pathways, making it valuable for studies involving immune response, cell proliferation, and apoptosis. Syk-IN-1 is suitable for research applications focused on hematological malignancies and inflammatory diseases, facilitating the exploration of Syk's role in various biological processes. -
SYK/ZAP70 Inhibitor
(R,S)-MK-8457 is a dual inhibitor of SYK and ZAP70, key signaling molecules involved in immune cell activation. This compound exhibits potent inhibitory activity, making it a valuable tool for investigating the pathophysiology of autoimmune disorders. Its application in research focuses primarily on the study of rheumatoid arthritis and other inflammatory conditions. -
SYK Inhibitor
Lanraplenib monosuccinate is a highly selective inhibitor of spleen tyrosine kinase (SYK), with an IC50 of 9.5 nM. This compound inhibits SYK activity in platelets through the glycoprotein VI (GPVI) receptor, making it a promising candidate for the treatment of inflammatory diseases. Notably, lanraplenib monosuccinate does not prolong bleeding time in preclinical models, indicating a favorable safety profile for potential therapeutic applications. -
Syk Inhibitor
Syk-IN-8 is a selective Syk inhibitor that exhibits significant antiproliferative activity against various hematological tumor cell lines. By targeting and inhibiting the phosphorylation of PLCγ2, Syk-IN-8 serves as a valuable tool for investigating the molecular mechanisms underlying blood cancers and evaluating potential therapeutic strategies. Its specificity and efficacy make it an important reagent for researchers focused on hematological malignancies.
